Beximco Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Beximco Pharmaceuticals has a total shareholder equity of BDT49.0B and total debt of BDT7.1B, which brings its debt-to-equity ratio to 14.5%. Its total assets and total liabilities are BDT70.6B and BDT21.6B respectively. Beximco Pharmaceuticals's EBIT is BDT7.3B making its interest coverage ratio 6.3. It has cash and short-term investments of BDT1.7B.
Key information
14.5%
Debt to equity ratio
৳7.10b
Debt
Interest coverage ratio | 6.3x |
Cash | ৳1.73b |
Equity | ৳49.04b |
Total liabilities | ৳21.58b |
Total assets | ৳70.63b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: R2WA's short term assets (BDT22.1B) exceed its short term liabilities (BDT13.6B).
Long Term Liabilities: R2WA's short term assets (BDT22.1B) exceed its long term liabilities (BDT8.0B).
Debt to Equity History and Analysis
Debt Level: R2WA's net debt to equity ratio (11%) is considered satisfactory.
Reducing Debt: R2WA's debt to equity ratio has reduced from 38.6% to 14.5% over the past 5 years.
Debt Coverage: R2WA's debt is well covered by operating cash flow (115.1%).
Interest Coverage: R2WA's interest payments on its debt are well covered by EBIT (6.3x coverage).